Press Release
iCo Therapeutics announces licensing deal
January 10, 2007
iCo Therapeutics has announced a licensing deal that gives it worldwide rights for the development and commercialization of CAT-213, a treatment for allergic disorders.
From the Vancouver Sun, by Gillian Shaw, an excerpt:
“Vancouver, BC: iCo Therapeutics has announced a licensing deal that gives it worldwide rights for the development and commercialization of CAT-213, a treatment for allergic disorders.
The announcement follows on the heels of the company’s recent announcement that it has filed an investigational new drug application with the U.S. Food and Drug Administration for iCo-007, its experimental treatment for eye diseases including age related macular degeneration and diabetic retinopathy.
And it propels the fledgling biotech into a clinical stage company, an accomplishment that typically takes years and tens of millions of dollars. …”
Read whole PDF article:
Vancouver Sun Jan 2007 iCo Therapeutics Licensing Deal.pdf
About iCo Therapeutics Inc.
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products, iCo-007, in Phase I for the treatment of Diabetic Macular Edema, iCo-008, a product with Phase II clinical history to be developed for severe ocular allergies, and iCo-009, a oral reformulation of Amphotericin B for sight and life – threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration.
iCo Therapeutics trades on the TSX-Venture exchange under the symbol “ICO”.
No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics’ current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Business Development Contact:
Dr. John Clement, CTO
604.602.9414 × 222
Finance Contact:
Mr. John Meekison, CFO
604.602.9414 × 224
Investor Contact:
Frederica Bell, Director, Corporate Development
604.602.9414 × 228